GSK Buys Aiolos Bio for Up to $1.4 Bln

GSK has acquired Aiolos Bio, a biopharmaceutical company specializing in respiratory and inflammatory conditions. The upfront consideration for the acquisition is $1.0 billion, with the potential for an additional $400 million.